Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19

NCT04252274 is registered in ClinicalTrials.gov with Shanghai Public Health Clinical Center as lead sponsor.

NCT NCT04252274
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04252274 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19
Lead sponsor
Shanghai Public Health Clinical Center
Phase
Phase 3
Overall status
Unknown status
Start date
January 30, 2020
Completion date
December 31, 2020
Enrollment
30 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus, pneumonia, pneumocystis